NastLaw LLC Updates on Antitrust Litigation Settlements
NastLaw LLC, alongside Direct Purchaser Plaintiffs, has initiated important class action settlements in an ongoing litigation concerning generic pharmaceutical pricing. If you are an individual or entity that directly purchased specific generic drugs from certain pharmaceutical manufacturers over a defined period, you may find this information particularly relevant.
Understanding the Nature of the Lawsuit
This litigation involves allegations against several generic drug manufacturers, including prominent names like Greenstone LLC, Pfizer Inc., and Glenmark Pharmaceutical Inc., who are collectively referred to as the Settling Defendants. The claim argues that these companies engaged in unlawful activities such as fixing and maintaining prices, rigging bids, and allocating market shares for certain generic medications. Such practices potentially led to consumers paying inflated prices for these essential drugs.
The Settling Defendants' Stance
While the Settling Defendants deny any wrongdoing as alleged in the lawsuit, it is noteworthy that the court has yet to determine the validity of the claims. Meanwhile, the case will continue against other defendants not involved in the current settlement. This development emphasizes that the journey towards justice in this matter is still in progress.
Criteria for Inclusion in the Settlement Classes
The court has certified two distinct Settlement Classes specifically tailored for the proposed settlements. The first class pertains to Greenstone and Pfizer, while the second revolves around Glenmark. Inclusion in either class is granted to all individuals or entities that directly acquired one or more of the relevant generic drugs from any of the Current or Former Defendants within the specified period.
Exclusions from the Settlement
However, certain parties are excluded from these Settlement Classes. This includes the Current and Former Defendants, along with their officers, directors, employees, and various associated entities. Such exclusions underscore the clear boundaries set around who may benefit from the settlements. A detailed listing of the implicated generic drugs and manufacturers is accessible through the official settlement website.
Insights into the Proposed Settlement Payments
The proposed class action settlements outline significant financial agreements, totaling an estimated $70,750,000, sourced primarily from Settling Defendants Greenstone and Pfizer, amounting to $33 million, and from Glenmark, totaling approximately $37.75 million. This Settlement Fund may be subject to reductions or increases based on specific criteria outlined in the Settlement Agreements.
Distribution of Settlement Funds
Direct Purchaser Plaintiffs' attorneys, who have diligently worked towards these settlements, will seek approval from the court for various expenses and service awards for class representatives. They will also request a set-aside for their fees out of the net Settlement Fund. Moreover, as part of the distribution process, DPP attorneys plan to allocate an additional $1,846,000 from other sources related to ongoing bankruptcies of certain defendants.
Your Potential Options and Next Steps
If you believe you are part of the Settlement Classes, you are not required to take any immediate action; remaining in the class allows you to potentially collect benefits under the settlements, should they proceed as planned. However, to receive any payments, it is essential to fill out and return the claim form once you receive it.
Exclusion and Objection Options
Settlement Class Members also retain the right to opt out of the settlements or voice objections before the court. For specific guidelines on how to navigate these options, refer to the publicly available case records. Requests to opt out or object must be submitted in writing by the designated deadline. A Fairness Hearing is scheduled, where the court will review the settlements and any objections raised.
Additional Resources for Interested Parties
For those seeking further information or clarification regarding the settlements and their implications, the settlement website provides comprehensive details. It includes essential lists of eligible drugs and manufacturers from whom purchases would have qualified you for settlement benefits. Additionally, you can reach out via provided contact numbers for personal inquiries.
Frequently Asked Questions
What is the purpose of these settlements?
These settlements aim to compensate those affected by alleged price-fixing and antitrust violations by certain generic drug manufacturers.
How can I confirm my eligibility for the settlement?
You must have directly purchased the described generic drugs from the indicated defendants during the class period to confirm eligibility.
What actions should I take if I want to opt out of the settlement?
You need to send your request to opt out in writing before the specified deadline to ensure your exclusion from the settlements.
When will claim forms be sent out?
Claim forms will be mailed to eligible class members, but the exact timing is currently unknown. Keep checking the settlement website for updates.
What happens at the Fairness Hearing?
The Fairness Hearing will consider the approval of the settlements and any objections. Participation is optional, but you must file a notice if you wish to attend or provide a statement.
